Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

C3G Disease Overview - C3G is a rare kidney disease with no specifically approved therapies, leading most patients to progress to kidney failure requiring dialysis or transplant [8] - Current treatments are complex and burdensome, often involving combinations of antihypertensive agents, SGLT2 inhibitors, corticosteroids, and immunosuppressive agents [9] - Nephrologists adjust treatment approaches based on eGFR decline and proteinuria levels, with SGLT2 inhibitor use increasing year-over-year [9] Physician Perspectives and Challenges - 148 nephrologists across EU5 countries emphasize the urgent need for effective C3G treatments and the importance of early intervention [1] - Less than half of EU5 nephrologists feel confident in achieving target proteinuria levels with current treatments [2] - Over 75% of audited C3G patients are expected to progress to end-stage renal disease within the next decade [2] Emerging Treatment Landscape - Promising new treatments in development include Novartis' Fabhalta (iptacopan) and Apellis' Empaveli (pegcetacoplan) [3] - Phase III APPEAR-C3G study showed Fabhalta plus supportive care achieved a 35.1% reduction in proteinuria at 6 months compared to placebo [10] - Additional pipeline assets from Q32 Bio, Omeros, and others offer hope for better C3G management [3] Market Research and Insights - Spherix's Patient Chart Dynamix™ service analyzes real patient management patterns and treatment decision drivers [4] - Market Dynamix™ provides analysis of markets expected to experience paradigm shifts in 3-5 years, including C3G [12] - Spherix monitors specialty markets across multiple therapeutic areas through its extensive Physician Community [13]